Loading...
Please wait, while we are loading the content...
Similar Documents
State-of-the-art treatment of chronic lymphocytic leukemia
| Content Provider | Scilit |
|---|---|
| Author | Hallek, Michael |
| Copyright Year | 2009 |
| Description | The last decade has produced rapid progress in the management of chronic lymphocytic leukemia (CLL). Fludarabine, bendamustine and two monoclonal antibodies, alemtuzumab and rituximab, have been approved by the European and/or American regulatory agencies. Several, novel monoclonal antibodies targeting CD20, CD23 or CD40, as well as drugs designed to interfere with proteins regulating the cell cycle, apoptotic machinery, or leukemic microenvironment (eg, flavopiridol, oblimersen, or lenalidomide), are currently being tested in clinical trials. Furthermore, the increased experience with reduced-intensity allogeneic progenitor cell transplantation allows offering this option to physically fit patients. In addition, new prognostic markers that may influence therapeutic decisions have been identified. This review attempts to summarize the current use of these different modalities in CLL therapy. |
| Related Links | http://asheducationbook.hematologylibrary.org/content/2009/1/440.full.pdf |
| Ending Page | 449 |
| Page Count | 10 |
| Starting Page | 440 |
| DOI | 10.1182/asheducation-2009.1.440 |
| Journal | Hematology |
| Issue Number | 1 |
| Volume Number | 2009 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2009-01-01 |
| Access Restriction | Open |
| Subject Keyword | Hematology Monoclonal Antibodies Proteins Cll Chronic Lymphocytic Leukemia Treatment Journal: Hematology (Vol- 29, Issue- 1) |
| Content Type | Text |
| Resource Type | Article |
